NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US

 NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US

NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US

Shots:

  • The results are concluded from 9 years’ study evaluating Next-Gen RNS System in 256 patients at 33 epilepsy centers, lacking adequate response to medications
  • The study demonstrated in 50% (3/4), 90% (1/3) reduction in seizures, median seizure reduction was 75%, six months or longer seizure-free periods 28%, seizure-free periods of one year or longer 18%, with improved QoL
  • Next-Gen RNS System is a FDA approved closed loop brain-responsive neurostimulation device with brain-computer interface, for continuous monitoring of brain waves recognizing each patient’s unique seizure onset pattern sending electrical pulses

Click here to read full press release/ article | Ref: Neuropace| Image: NeuroPace, Inc 

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post